Physician profile
Jay P Gray
NPI 1205211497
$10,432.75
in general payments reported to CMS, 2019-2025
31 companies · $2,115 in 2025
The $2,115 reported for 2025 was more than what 93% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $909 · 2022: $1,191 · 2023: $2,925 · 2024: $3,294 · 2025: $2,115.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,733 · Consulting Fee: $600.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,733.38 |
| Consulting Fee | $600.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,612.37 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $843.26 | 2022-2025 | Winlevi, Blu-U, Ilumya |
| Almirall LLC | $823.83 | 2021-2024 | Seysara, Klisyri |
| E.R. Squibb & Sons, L.L.C. | $786.34 | 2022-2025 | Sotyktu |
| Lilly USA, LLC | $749.76 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Amgen INC. | $723.45 | 2021-2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $543.80 | 2022-2025 | |
| Incyte Corporation | $518.52 | 2021-2025 | Opzelura |
| Dermavant Sciences, INC. | $475.37 | 2022-2024 | Vtama |
| Janssen Biotech, INC. | $441.60 | 2021-2025 | Tremfya |
| Ucb, INC. | $437.67 | 2021-2025 | Bimzelx, Cimzia |
| Regeneron Healthcare Solutions, INC. | $410.33 | 2021-2025 | Dupixent, Libtayo |
| Leo Pharma INC. | $339.90 | 2022-2025 | Adbry |
| Galderma Laboratories, L.P. | $295.34 | 2021-2024 | Aklief |
| Genzyme Corporation | $189.60 | 2021-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $177.11 | 2021-2023 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $174.13 | 2022-2025 | Cabtreo, Arazlo |
| Mayne Pharma Commercial LLC | $169.08 | 2021-2025 | |
| Arcutis Biotherapeutics, INC. | $166.22 | 2024-2025 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.92 | 2022-2025 | Spevigo, Cyltezo |
| Stemline Therapeutics INC. | $104.87 | 2021 | |
| Organon LLC | $88.66 | 2023-2025 | Vtama, Hadlima |
| Mallinckrodt Hospital Products INC. | $43.11 | 2025 | Acthar |
| Janssen Pharmaceuticals, INC | $42.74 | 2024 | Tremfya |
| Kyowa Kirin, INC. | $30.11 | 2022-2023 | Poteligeo |
| Fresenius Kabi USA, LLC | $28.93 | 2023 | Idacio |
| Organogenesis INC. | $23.81 | 2025 | Nushield |
| Blueprint Medicines Corporation | $21.83 | 2023 | |
| Strata Skin Sciences, INC. | $19.92 | 2025 | Xtrac |
| Verrica Pharmaceuticals INC. | $18.09 | 2024 | Ycanth |
| Biofrontera INC. | $18.08 | 2024 | Xepi, Bf-Rhodoled, Ameluz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Gray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.